172 related articles for article (PubMed ID: 28285389)
1. Treatment satisfaction of patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents.
Marakis TP; Koutsandrea C; Chatzistefanou KI; Tountas Y
Int Ophthalmol; 2018 Apr; 38(2):565-576. PubMed ID: 28285389
[TBL] [Abstract][Full Text] [Related]
2. Reliability, validity and responsiveness of the Greek MacDQoL individualized measure of the impact of macular degeneration on quality of life.
Marakis TP; Koutsandrea C; Chatzistefanou KI; Tountas Y
Qual Life Res; 2017 Jan; 26(1):183-191. PubMed ID: 27614659
[TBL] [Abstract][Full Text] [Related]
3. Treatment Satisfaction and Well-Being in Patients with Myopic Choroidal Neovascularization Treated with Ranibizumab in the REPAIR Study.
Amoaku WM; Gale RP; Lotery AJ; Menon G; Sivaprasad S; Petrillo J; Quinn J
PLoS One; 2015; 10(6):e0128403. PubMed ID: 26039355
[TBL] [Abstract][Full Text] [Related]
4. NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH ADVANCED VISUAL LOSS TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: Clinical Outcome and Prognostic Indicators.
Vogel RN; Davis DB; Kimura BH; Rathinavelu S; Graves GS; Szabo A; Han DP
Retina; 2017 Feb; 37(2):257-264. PubMed ID: 27429385
[TBL] [Abstract][Full Text] [Related]
5. The impact of anti-vascular endothelial growth factor treatment on quality of life in neovascular age-related macular degeneration.
Finger RP; Guymer RH; Gillies MC; Keeffe JE
Ophthalmology; 2014 Jun; 121(6):1246-51. PubMed ID: 24518613
[TBL] [Abstract][Full Text] [Related]
6. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.
Kaiser PK; Brown DM; Zhang K; Hudson HL; Holz FG; Shapiro H; Schneider S; Acharya NR
Am J Ophthalmol; 2007 Dec; 144(6):850-857. PubMed ID: 17949673
[TBL] [Abstract][Full Text] [Related]
7. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
Boyer DS; Antoszyk AN; Awh CC; Bhisitkul RB; Shapiro H; Acharya NR;
Ophthalmology; 2007 Feb; 114(2):246-52. PubMed ID: 17270674
[TBL] [Abstract][Full Text] [Related]
8. The neovascular age-related macular degeneration database: report 2: incidence, management, and visual outcomes of second treated eyes.
Zarranz-Ventura J; Liew G; Johnston RL; Xing W; Akerele T; McKibbin M; Downey L; Natha S; Chakravarthy U; Bailey C; Khan R; Antcliff R; Armstrong S; Varma A; Kumar V; Tsaloumas M; Mandal K; Bunce C; Tufail A;
Ophthalmology; 2014 Oct; 121(10):1966-75. PubMed ID: 24953791
[TBL] [Abstract][Full Text] [Related]
9. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial.
Bressler NM; Chang TS; Fine JT; Dolan CM; Ward J;
Arch Ophthalmol; 2009 Jan; 127(1):13-21. PubMed ID: 19139332
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
Hernandez-Pastor LJ; Ortega A; Garcia-Layana A; Giraldez J
Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
[TBL] [Abstract][Full Text] [Related]
11. TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN.
Rahimy E; Rayess N; Ho AC; Regillo CD
Retina; 2016 May; 36(5):875-80. PubMed ID: 26630316
[TBL] [Abstract][Full Text] [Related]
12. Changes in Fundus Autofluorescence after Anti-vascular Endothelial Growth Factor According to the Type of Choroidal Neovascularization in Age-related Macular Degeneration.
Lee JY; Chung H; Kim HC
Korean J Ophthalmol; 2016 Feb; 30(1):17-24. PubMed ID: 26865799
[TBL] [Abstract][Full Text] [Related]
13. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) in a Norwegian population of patients with neovascular age-related macular degeneration compared to a control population.
Jelin E; Wisløff T; Moe MC; Heiberg T
Health Qual Life Outcomes; 2019 Aug; 17(1):140. PubMed ID: 31412873
[TBL] [Abstract][Full Text] [Related]
14. The impact of vision impairment on vision-related quality of life of patients with neovascular age-related macular degeneration.
Marakis TP; Koutsandrea C; Poulou MS
Eur J Ophthalmol; 2022 Jan; 32(1):481-490. PubMed ID: 33213182
[TBL] [Abstract][Full Text] [Related]
15. Patients' preferences in treatment for neovascular age-related macular degeneration in clinical routine.
Finger RP; Hoffmann AE; Fenwick EK; Wolf A; Kampik A; Kernt M; Neubauer AS; Hirneiss C
Br J Ophthalmol; 2012 Jul; 96(7):997-1002. PubMed ID: 22535331
[TBL] [Abstract][Full Text] [Related]
16. Modifiable Determinants of Satisfaction with Intravitreal Treatment in Patients with Neovascular Age-Related Macular Degeneration.
Calles-Monar PS; Sanabria MR; Alonso-Tarancon AM; Coco-Martin RM; Mayo-Iscar A
Drugs Aging; 2022 May; 39(5):355-366. PubMed ID: 35486357
[TBL] [Abstract][Full Text] [Related]
17. Ranibizumab treatment in patients with neovascular age-related macular degeneration and very low vision.
Sørensen TL; Kemp H
Acta Ophthalmol; 2011 Feb; 89(1):e97. PubMed ID: 20384603
[No Abstract] [Full Text] [Related]
18. Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration.
Zhu M; Wijeyakumar W; Syed AR; Joachim N; Hong T; Broadhead GK; Li H; Luo K; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):475-484. PubMed ID: 27572301
[TBL] [Abstract][Full Text] [Related]
19. Neovascular age-related macular degeneration treated with ranibizumab or aflibercept in the same large clinical setting: visual outcome and number of injections.
Rasmussen A; Sander B; Larsen M; Brandi S; Fuchs J; Hansen LH; Lund-Andersen H
Acta Ophthalmol; 2017 Mar; 95(2):128-132. PubMed ID: 27535819
[TBL] [Abstract][Full Text] [Related]
20. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial.
Chang TS; Bressler NM; Fine JT; Dolan CM; Ward J; Klesert TR;
Arch Ophthalmol; 2007 Nov; 125(11):1460-9. PubMed ID: 17998507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
